FASS logotyp

Peka på symbolerna och beteckningarna till vänster för en förklaring.


Sök apotek med läkemedlet i lager

Sök lagerstatus


Sanofi AB

Filmdragerad tablett 10 mg
(vit till nästan vit, rund med ZBN graverat på ena sidan, storlek 7,1 mm x 7,1 mm)

Immunmodulerande medel

Aktiv substans:
ATC-kod: L04AA13
Läkemedel från Sanofi AB omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?




Miljörisk: Användning av leflunomid har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Leflunomid är potentiellt persistent.
Bioackumulering: Leflunomid har låg potential att bioackumuleras.

Läs mer

Detaljerad miljöinformation

Environmental Risk Classification

Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:

PEC (µg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.5*10-6*A*(100-R)

PEC = 0.0013 µg/L


A = 8.6119 kg (total sold amount API in Sweden year 2017, data from OQVIA)

R = 0% removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation)

P = number of inhabitants in Sweden = 9*106

V (L/day) = volume of wastewater per capita and day = 200 (Ref I)

D = factor of dilution of waste water by surface water flow = 10 (Ref I)

According to the European Medicines Agency guideline on environmental risk
assessment of medicinal products (EMA/CHMP/SWP/4447/00), use of leflunomid is unlikely to represent a risk for the environment, because the predicted
environmental concentration (PEC) is below the action limit 0.01 µg/L.

Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Green algae, Desmodesmus subspicatus:

Acute toxicity, leflunomide

EC50 72 h (growth rate, biomass): 22 420 μg/L

(Protocol: OECD 201)

(Ref II)

Green algae, Selenastrum capricornutum:

Acute toxicity, A771726 (active metabolite)

EC50 72 h (growth rate, biomass): 22 800 μg/L

(Protocol: OECD 201)

(Ref III)

Water flea, Daphnia magna:

Acute toxicity, leflunomide

EC50 48 h (immobility): 17 000 μg/L

(Protocol: OECD 202)

(Ref IV)

Acute toxicity, A771726 (active metabolite)

EC50 48 h (immobility): > 100 000 μg/L

(Protocol: OECD 202)

(Ref III)

Zebrafish, Brachydanio rerio:

Acute toxicity, leflunomide
LC50 96 h (survival): 2 640 μg/L

(Protocol: OECD 203)

(Ref V)

Acute toxicity, A771726 (active metabolite)

LC50 96 h (survival): 50 000 – 100 000 μg/L

(Protocol: OECD 203)

(Ref III)

Other ecotoxicity data:

PNEC = 2.64 ug/L

PNEC (μg/L) = 2 640/1 000, where 1 000 is the assessment factor used (acute toxicity data only). EC50 for Zebrafish, Danio rerio has been used for this calculation since it is the most sensitive of the three tested species for the parent compound, leflunomide. Given that the acute toxicity values for the active metabolite A771726 are all greater than those for leflunomide, including by an order of magnitude in fish, the calculated PNEC value is sufficient for classification of environmental risk for leflunomide.

Environmental Risk Classification (PEC/PNEC ratio)

PEC/PNEC= 0.0013/2.64 = 0.00049

PEC/PNEC ≤ 0.1 which justifies the phrase “Use of leflunomide has been considered to result in insignificant environmental risk.” This ratio also assumes that 100 % of leflunomide excreted is pharmacologically active, whereas the percentage of the active metabolite is actually 45 – 50 % (see Excretion).


Biotic degradation

Leflunomide is potentially persistent with less than 20 % of the substance being degraded in 28 days (OECD 301B) (Ref VI).

The active metabolite A771726 is not readily biodegradable (approximately 1 %) over a 28 day period (OECD 301E) (Ref VII).

Abiotic degradation

Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions.


Partitioning coefficient:

Log Pow = 3.49 has been experimentally determined (method unknown) for leflunomide (Ref III).

Log Pow = 0,925 at pH 7 for the active metabolite A771726 Teriflunomide (test protocol OECD107) (Ref VIII).

Leflunomide is unlikely to be bioaccumulable in living organisms (Log Kow < 4) (Ref IX).

Since log Pow < 4 at pH 7 the active metabolite has low potential for bioaccumulation.


Following oral administration, leflunomide is metabolized to one major and pharmacological active metabolite, A771726, responsible for essentially all of its activity in vivo. In addition many minor metabolites are formed with unknown pharmacological activity. Of these minor metabolites, only 4-trifluoromethylaniline (TFMA) is quantifiable, occurring at low levels in the plasma in some patients. 45 to 50 % of the total dose is excreted as the active metabolite A771726. (Ref X)


  1. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment.

  2. Internal report, Aventis Pharma Deutschland: Growth Inhibition Test with Fresh Water Algae (Desmodesmus subspicatis). OECD 201. Report # PT02-0120, January 2003.

  3. 7. Internal report, Hoechst AG: Leflunomide Environmental Risk Assessment. Report # 016723, August 1997.

  4. 3. Internal report, Hoechst AG: Acute Toxicity Study on Daphnia. OECD 202. Report # 96.0333, May 1996.

  5. 4. Internal report, Hoechst AG: Acute Toxicity Study on Zebra Fish. OECD 203. Report # 93.0532, September 1993.

  6. 6. Internal report, Hoechst AG: Study of Biodegradability of Leflunomide, OECD 301B. Report # 93-0111-42, October 1993.

  7. 9. Internal report, Hoechst AG: Study of Biodegradability of A771726, OECD 301E.

  8. Internal report, Wildlife International Ltd: Teriflunomide - Determination of the n-octanol/water partition coefficient by the shake flask method. OECD107. Report # 647C-130, June 2012

  9. Internal document by Winthrop, a Sanofi company. February 2017; Third version. Retrieved March 14 2019, from https://www.winthropus.com/docs/leflunomide%20tablets_winthrop%20feb%202017.pdf.

  10. Package insert: Arava, Sanofi-Aventis U.S. LLC, 2012.